T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and Rhizen Pharmaceuticals [Yaho...
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Yahoo! Finance
T-Cell lymphoma is a type of non-Hodgkin lymphoma that originates in T-Cells, a vital component of the immune system. This cancer is characterized by the rapid growth and proliferation of malignant T-Cells, leading to various symptoms, including swollen lymph nodes, skin rashes, and systemic involvement. It accounts for about 10-15% of all non-Hodgkin lymphomas, with a higher prevalence in older adults. Key Takeaways Key players in the T-Cell lymphoma drug pipeline market include Legend Biotech USA Inc., Eisai Inc., Takeda, Corvus Pharmaceuticals, Inc., Rhizen Pharmaceuticals SA, and Antengene Corporation. These companies are at the forefront of developing cutting-edge therapies to improve patient outcomes. The drug pipeline for T-Cell lymphoma includes promising candidates such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. These treatments focus on modulating the immune response, targeting specific cancer cell markers, and providing innovative approaches to control th
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor ImmunityGlobeNewswire
- Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis [Yahoo! Finance]Yahoo! Finance
CRVS
Earnings
- 11/12/24 - Miss
CRVS
Sec Filings
- 12/23/24 - Form 4
- 12/23/24 - Form 4
- 12/23/24 - Form 4
- CRVS's page on the SEC website